Talquetamab Multiple Myeloma: Impact, Evidence,...

By Staff Writer

July 9, 2025

Talquetamab multiple myeloma is an emerging treatment option for adults with relapsed and refractory multiple myeloma (RRMM) who have progressed after at least three prior therapies. For patients facing limited options, how does talquetamab (marke...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.